Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGS-MRD Evaluation of Antigen-specific T Cells and DC Vaccine Combination Targeting T-ALL
NCT05277753Phase 1Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA and WT1/hTERT/Survivin-loaded dendritic cell vaccine in T cell acute lymphoblastic leukemia (T-ALL), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoints: Treatment-related adverse events at 1 year, Clinical response at 1 year and 1 more. Started Jun 2026; status: terminated.
02
Drugs
CART-BCMAWT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
T cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT05277753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05277753.